title: Resurrected cancer drug faces regulators.
authors: Heidi
authors: H
authors: Ledford
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004260:DNA Repair / Q000235:genetics; D017277:Drug Approval; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics; D010793:Phthalazines / Q000494:pharmacology / Q000627:therapeutic use; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C090712:iniparib; C531549:rucaparib; D011065:Poly(ADP-ribose) Polymerases; C531550:olaparib